ADVITOS GmbH
Desconocido
ADVOS-COVID-19: Increasing Survival of Patients with Severe SARS CoV 2 Infection and or Multi Organ Failure by up to...
ADVITOS GMBH
tramitó un
H2020:
H2020-EIC-SMEInst-2018-2020
ADVITOS` innovation – the ADVOS therapy system - has the potential to increase the survival of COVID-19 patients suffering from severe multi...
2020-07-27 - 2023-06-30 | Financiado
2020-07-27 - 2023-06-30 | Financiado
ADVOS: ADVanced Organ Support Revolution in intensive care for treatment of multiple organ failure
ADVITOS GMBH
tramitó un
H2020:
H2020-EIC-SMEInst-2018-2020
60% of intensive care patients die of multiple organ failure (MOF), resulting in a market potential in Western EU of €1.19bn in 13 targeted...
2019-10-16 - 2022-04-30 | Financiado
2019-10-16 - 2022-04-30 | Financiado
* No se disponen de datos de la empresa actual.